Patricia Maeda

  • Citations Per Year
Learn More
INTRODUCTION Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. In this randomized, double-blind, placebo-controlled phase III trial, we assessed first- or(More)
  • 1